Australia markets open in 5 hours

ABBV Jan 2025 115.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.22000.0000 (0.00%)
As of 01:31PM EST. Market open.
Full screen
Previous close1.2200
Open1.2200
Bid0.8700
Ask1.3200
Strike115.00
Expiry date2025-01-17
Day's range1.2200 - 1.2200
Contract rangeN/A
Volume3
Open interest3.53k
  • PR Newswire

    AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

    AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles™ platform.

  • Reuters

    UPDATE 1-AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports

    AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. AbbVie did not immediately respond to Reuters' request for a comment. In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.

  • Bloomberg

    AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A

    (Bloomberg) -- Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.Most Read from BloombergNvidia Surges After Company Proclaims AI Has Hit 'Tipping Point'Biden Touts $1.2 Billion in Student Loan Relief With Eye to 2024Tech Up in Late Hours on Nvidia’s Bullish Outlook: Markets WrapChina Tightens Grip on Stocks With Net Sa